Thus, several studies have reported that FABP5 was upregulated in cholangiocarcinoma and hepatocellular carcinoma, prostatic carcinoma, glioma, oral squamous cell carcinoma, cervical cancer, colorectal cancer, pancreatic cancer, non-small cell lung cancer, breast cancer25. Here, FABP5 is linked to cholangiocarcinoma.